HeartBeam (BEAT) Expected to Release Quarterly Earnings on Thursday

HeartBeam (NASDAQ:BEAT) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $0.07 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

HeartBeam (NASDAQ:BEAT) last released its quarterly earnings data on Thursday, August 13th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, analysts expect HeartBeam to post ($0.37) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

HeartBeam Trading Down 1.4%

Shares of NASDAQ BEAT opened at $0.42 on Thursday. The company has a 50 day simple moving average of $0.44 and a 200 day simple moving average of $0.85. HeartBeam has a 1 year low of $0.35 and a 1 year high of $4.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BEAT shares. HC Wainwright reissued a “neutral” rating on shares of HeartBeam in a report on Tuesday, October 6th. Weiss Ratings upgraded shares of HeartBeam from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Maxim Group assumed coverage on shares of HeartBeam in a report on Tuesday, July 14th. They set a “buy” rating and a $2.00 price target on the stock. Finally, Wall Street Zen raised HeartBeam to a “sell” rating in a report on Saturday, October 10th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

HeartBeam Company Profile

HeartBeam, Inc is a medical technology company developing portable and digital solutions for cardiac monitoring. Its proprietary technology is designed to capture, analyze and transmit electrocardiogram (ECG) data outside traditional clinical settings, with a focus on helping identify cardiac events such as atrial fibrillation and heart attacks.

The company’s flagship product is the HeartBeam AIMIGo system, which combines a compact, credit-card-sized ECG device with a smartphone application.